Replies to post #12971 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

On its innovative products, MNTA could report more data on necuparanib (metastatic pancreatic cancer) Phase I/II dose escalation studies; Part A top-line results were promising.

I recall that Momenta was submitting the M402 to Asco for the Gastro Conference but that conference was last week and I didn't see a presentation.

Oh well.......